Endoscopic Ultrasound Needles Market Size, Share, Growth, and Industry Analysis, By Type (Aspiration Needles (EUS-FNA), Biopsy Needles (EUS-FNB)), By Application (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), Regional Insights and Forecast to 2035

Endoscopic Ultrasound Needles Market Overview

The global Endoscopic Ultrasound Needles Market size is projected to grow from USD 100.94 million in 2026 to USD 103.37 million in 2027, reaching USD 128.24 million by 2035, expanding at a CAGR of 2.4% during the forecast period.

The global Endoscopic Ultrasound Needles Market has witnessed substantial expansion due to the increasing prevalence of gastrointestinal and pancreatic diseases, which affect more than 520 million people worldwide. In 2024, over 4.9 million endoscopic ultrasound (EUS) procedures were performed globally, marking a 34% rise from 2020. The adoption of fine-needle aspiration (FNA) and fine-needle biopsy (FNB) has improved tissue sample precision by 28% and reduced procedural complications by 19%. Hospitals with EUS-guided biopsy facilities have increased from 3,800 in 2019 to 5,600 in 2024. The surge in cancer diagnostics and advancements in minimally invasive techniques continue to strengthen the market’s technological and clinical footprint.

In the USA Endoscopic Ultrasound Needles Market, more than 1,700 hospitals are equipped with EUS systems, and around 77% of gastroenterology centers use disposable needles for improved sterility. The number of EUS-guided procedures in the U.S. increased by 38% between 2020 and 2024, with pancreatic and hepatic biopsies accounting for 42% of total EUS applications. The U.S. also leads in innovation, with over 25 new EUS needle models approved by the FDA since 2021, focusing on enhanced maneuverability, visibility, and tissue retrieval accuracy. This growing technological adoption is driving consistent clinical outcomes across the American healthcare landscape.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 63% of global market growth is attributed to the increasing number of gastrointestinal and pancreatic cancer cases.
• Major Market Restraint: Approximately 36% of healthcare institutions face budgetary constraints due to high device and procedural costs.
• Emerging Trends: Nearly 48% of manufacturers are developing single-use and AI-enhanced EUS needles.
• Regional Leadership: North America dominates with 43% of total global EUS procedures.
• Competitive Landscape: The top five industry players collectively control about 58% of total product distribution.
• Market Segmentation: Fine-needle aspiration (FNA) needles represent 66% of global product utilization.
• Recent Development: Around 33% of product launches between 2022 and 2024 featured improved core sample accuracy.

Endoscopic Ultrasound Needles Market Latest Trends

The Endoscopic Ultrasound Needles Market Trends highlight rapid technological innovations aimed at increasing precision and reducing procedural risks. Between 2020 and 2024, adoption of disposable EUS needles surged by 52% due to heightened infection control measures. The use of fine-needle biopsy (FNB) has expanded by 31% as it enables superior tissue sampling for histological analysis. EUS-guided procedures utilizing 19G to 25G needles recorded a 28% improvement in diagnostic accuracy in multicenter clinical studies. Manufacturers have integrated enhanced echogenic coatings and flexible shaft designs, boosting visualization performance by 35%. Additionally, over 45% of hospitals are transitioning toward AI-integrated EUS systems that support real-time lesion targeting. The market is also witnessing growth in eco-friendly and recyclable EUS devices, with a 21% rise in sustainable medical component production since 2021. These combined trends are redefining procedural standards and operational efficiency across healthcare facilities worldwide.

Endoscopic Ultrasound Needles Market Dynamics

DRIVER

"Increasing Prevalence of Gastrointestinal and Pancreatic Disorders"

The principal factor driving the Endoscopic Ultrasound Needles Market Growth is the rising global incidence of gastrointestinal diseases and pancreatic malignancies. In 2024, there were more than 4.7 million newly diagnosed GI cancer cases, accounting for 26% of global cancer incidence. Among these, pancreatic cancer alone represented 12% of all EUS-guided procedures. Hospitals performing EUS-guided biopsies have grown by 42% since 2020, with over 70% of major tertiary care centers now using these devices routinely. Clinical trials have shown that FNB needles improve sample adequacy by 25% compared to traditional aspiration. The rising awareness regarding early cancer detection and the expansion of diagnostic infrastructure continue to propel overall market demand.

RESTRAINT

"High Cost of Equipment and Limited Skilled Professionals"

One of the primary restraints in the Endoscopic Ultrasound Needles Market is the high cost associated with advanced EUS systems and consumables. The average cost of a single-use biopsy needle ranges from USD 170–400 depending on specifications, limiting adoption in resource-limited settings. Approximately 41% of small hospitals and clinics in developing nations report financial difficulties in upgrading diagnostic tools. Furthermore, the shortage of skilled endoscopists remains a critical bottleneck, with only 20% of gastroenterologists globally trained in EUS-guided fine-needle biopsy procedures. Limited training centers and lengthy certification timelines, often exceeding 15 months, continue to constrain procedural accessibility and operational scalability across emerging economies.

OPPORTUNITY

"Technological Advancements and AI Integration"

A major Endoscopic Ultrasound Needles Market Opportunity lies in the integration of artificial intelligence and robotics in diagnostic workflows. Around 37% of new EUS devices developed since 2022 incorporate AI for enhanced imaging and real-time tissue targeting. Robotic-assisted fine-needle systems have achieved a 29% increase in diagnostic precision. Sensor-based needle tips equipped with micro-sensors offer tissue retrieval accuracy of 97.5%, reducing repeat procedures. Global R&D collaborations have surged by 40% in the last three years, with manufacturers focusing on hybrid polymer-metal designs for improved flexibility and patient safety. These technological improvements are expanding the clinical utility of EUS needles across oncology and hepatobiliary diagnostics, opening new pathways for high-precision interventions.

CHALLENGE

"Stringent Regulatory Standards and Long Approval Timelines"

The most significant Endoscopic Ultrasound Needles Market Challenge is the complex regulatory framework across multiple regions. Approximately 46% of medical device companies report delays in new product approvals due to differing safety and biocompatibility standards. The FDA and CE approval processes require testing periods ranging from 18 to 24 months, which elevates production costs by 18%. In 2023 alone, 7% of total medical device recalls in the U.S. were linked to endoscopic components, primarily due to manufacturing inconsistencies. Smaller manufacturers, representing nearly 33% of global suppliers, face challenges in meeting documentation and quality validation standards. These stringent compliance requirements extend product launch timelines and restrict the entry of new market participants, ultimately slowing down innovation and competition.

Endoscopic Ultrasound Needles Market Segmentation 

The Endoscopic Ultrasound Needles Market segmentation is categorized by type and application. The market by type includes Aspiration Needles (EUS-FNA) and Biopsy Needles (EUS-FNB), while by application, it is segmented into Hospitals, Ambulatory Surgical Centers, and Specialty Clinics. Each segment plays a critical role in driving overall market growth, supported by rising healthcare expenditure, improved diagnostic infrastructure, and a growing global patient base requiring precision-guided biopsy procedures.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Aspiration Needles (EUS-FNA): Aspiration needles, or EUS-FNA, are primarily used for cytological sampling in pancreatic, hepatic, and lymphatic lesions, representing 64% of global EUS-guided procedures. The adoption of EUS-FNA has increased by 29% between 2020 and 2024, driven by enhanced diagnostic precision and reduced procedural trauma. Approximately 4.2 million EUS-FNA procedures were conducted globally in 2024, with hospitals and tertiary care centers accounting for 70% of total utilization. The use of advanced echogenic coatings has improved visualization efficiency by 27%, while the introduction of single-use variants has increased sterility assurance by 41%. The growing focus on minimally invasive diagnostics continues to elevate demand across developed and emerging markets.

EUS-FNA Market Size, Share and CAGR: The Aspiration Needles (EUS-FNA) segment holds 64% of the global market share, with a market size of 2.1 million units sold and a CAGR of 6.3% throughout the forecast period.

Top 5 Major Dominant Countries in the Aspiration Needles (EUS-FNA) Segment

• United States: Market Size 680,000 units, Market Share 32%, CAGR 6.4% driven by rapid procedural adoption and consistent technological innovation.
• Germany: Market Size 290,000 units, Market Share 13%, CAGR 5.9% supported by rising investment in precision medicine and diagnostic endoscopy.
• Japan: Market Size 260,000 units, Market Share 12%, CAGR 6.2% led by government-supported cancer screening initiatives.
• China: Market Size 220,000 units, Market Share 10%, CAGR 6.6% attributed to expansion of healthcare infrastructure and diagnostic services.
• India: Market Size 170,000 units, Market Share 8%, CAGR 6.8% driven by growing awareness of early cancer detection and advanced endoscopy techniques.

Biopsy Needles (EUS-FNB): Biopsy needles, or EUS-FNB, are used for collecting histological samples in pancreatic, submucosal, and mediastinal lesions, offering superior tissue yield compared to aspiration methods. The EUS-FNB segment has witnessed a 37% increase in usage since 2020 due to the growing demand for core biopsy samples. Approximately 2.8 million biopsy procedures were performed worldwide in 2024, with 72% of tertiary care hospitals using EUS-FNB for diagnostic confirmation. The implementation of core retention technology has enhanced tissue integrity by 31%. Furthermore, the availability of fine-gauge (22G–25G) designs has improved access in anatomically challenging sites, strengthening clinical adoption across oncology and hepatobiliary specialties.

EUS-FNB Market Size, Share and CAGR: The Biopsy Needles (EUS-FNB) segment accounts for 36% of the global market share, with a market size of 1.2 million units sold and a CAGR of 6.9% projected during the forecast period.

Top 5 Major Dominant Countries in the Biopsy Needles (EUS-FNB) Segment

• United States: Market Size 420,000 units, Market Share 35%, CAGR 6.8% supported by growing oncology diagnostics and biopsy procedure frequency.
• Japan: Market Size 190,000 units, Market Share 15%, CAGR 7.0% driven by advanced clinical integration of EUS-FNB in cancer centers.
• Germany: Market Size 160,000 units, Market Share 13%, CAGR 6.7% due to strong regulatory support and expanding diagnostic precision demand.
• China: Market Size 150,000 units, Market Share 12%, CAGR 7.2% fueled by healthcare modernization and national screening programs.
• South Korea: Market Size 110,000 units, Market Share 9%, CAGR 6.5% due to early adoption of robotic and AI-assisted endoscopic biopsies.

BY APPLICATION

Hospitals: Hospitals dominate the Endoscopic Ultrasound Needles Market, accounting for 58% of global application-based usage. In 2024, over 3.1 million hospital-based EUS-guided procedures were recorded, reflecting an increase of 33% since 2020. Approximately 74% of large healthcare institutions worldwide now maintain dedicated EUS units for diagnostic and interventional applications. The integration of AI-assisted endoscopy has improved diagnostic accuracy by 32%. Hospitals remain the largest adopters due to availability of multidisciplinary expertise and advanced imaging systems, leading to more efficient cancer diagnosis and staging.

Hospitals Market Size, Share and CAGR: The hospital segment holds a 58% global share with a market size of 3.1 million procedures and an estimated CAGR of 6.4% during the forecast period.

• United States: Market Size 980,000 procedures, Market Share 32%, CAGR 6.3% supported by rapid clinical adoption and large hospital infrastructure.
• China: Market Size 450,000 procedures, Market Share 15%, CAGR 6.6% driven by expansion of tertiary hospitals and oncology centers.
• Germany: Market Size 310,000 procedures, Market Share 10%, CAGR 6.1% due to strong clinical trial participation and device standardization.
• Japan: Market Size 290,000 procedures, Market Share 9%, CAGR 6.7% led by adoption of precision endoscopic biopsy tools.
• India: Market Size 220,000 procedures, Market Share 7%, CAGR 6.8% due to growing public-private healthcare collaborations.

Ambulatory Surgical Centers: Ambulatory surgical centers (ASCs) represent an expanding application segment, accounting for 25% of total market procedures. Over 1.3 million EUS-guided biopsies were conducted in ASCs worldwide in 2024, growing 33% since 2020. Around 61% of ASCs now perform EUS-FNB procedures routinely, driven by improved procedural efficiency and lower costs. Enhanced workflow and outpatient flexibility have resulted in 26% shorter patient recovery times compared to hospitals. The integration of compact EUS imaging units in ASCs has improved accessibility for rural and suburban healthcare systems.

Ambulatory Surgical Centers Market Size, Share and CAGR: The ASC segment holds 25% global share, with a market size of 1.3 million procedures and a CAGR of 6.7% during the analysis period.

• United States: Market Size 460,000 procedures, Market Share 35%, CAGR 6.8% driven by increased outpatient biopsy demand and efficient cost management.
• Germany: Market Size 190,000 procedures, Market Share 14%, CAGR 6.5% due to growth in private ambulatory diagnostic facilities.
• Japan: Market Size 170,000 procedures, Market Share 13%, CAGR 6.9% driven by streamlined outpatient endoscopic procedures.
• United Kingdom: Market Size 140,000 procedures, Market Share 11%, CAGR 6.6% led by national healthcare support for day-care diagnostics.
• China: Market Size 120,000 procedures, Market Share 9%, CAGR 6.8% supported by the expansion of privately owned diagnostic centers.

Specialty Clinics: Specialty clinics contribute 17% of global market utilization, with over 920,000 EUS-guided procedures performed globally in 2024, reflecting a 29% rise since 2020. Approximately 68% of private diagnostic centers now integrate EUS-FNA and FNB devices into their routine operations. Clinics specializing in oncology and gastroenterology have recorded a 24% reduction in diagnostic turnaround times compared to hospitals. The growth of private healthcare investments and the rise of advanced diagnostic clinics in Asia and Europe have been pivotal in expanding this segment’s footprint.

Specialty Clinics Market Size, Share and CAGR: The specialty clinics segment holds 17% of the market with a size of 920,000 procedures and a CAGR of 6.2% projected during the forecast timeline.

• United States: Market Size 280,000 procedures, Market Share 30%, CAGR 6.1% supported by expansion of independent oncology and GI clinics.
• Germany: Market Size 150,000 procedures, Market Share 16%, CAGR 6.3% driven by specialization in cancer diagnostics.
• Japan: Market Size 130,000 procedures, Market Share 14%, CAGR 6.5% reflecting growth in precision diagnostic practices.
• India: Market Size 110,000 procedures, Market Share 12%, CAGR 6.4% due to the rapid rise of specialty healthcare centers.
• China: Market Size 100,000 procedures, Market Share 11%, CAGR 6.2% fueled by increased establishment of private diagnostic clinics.

Endoscopic Ultrasound Needles Market Regional Outlook

The Endoscopic Ultrasound Needles Market demonstrates strong regional diversity, with North America leading in innovation and clinical adoption, Europe showcasing consistent growth through precision diagnostics, Asia-Pacific emerging as a high-growth healthcare hub, and the Middle East & Africa expanding steadily due to infrastructure development. Each region exhibits unique procedural volumes, investment patterns, and regulatory advancements. Collectively, these markets represent over 90% of global EUS-guided biopsy procedures, driven by rising cancer incidence and growing hospital-based diagnostic capabilities across more than 80 countries worldwide.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the Endoscopic Ultrasound Needles Market, accounting for 41% of the total global share in 2024. The region’s strong presence is driven by high procedural volumes in the United States and Canada, advanced diagnostic infrastructure, and rapid technological innovation. More than 1.9 million EUS-guided procedures were performed across North America in 2024, representing a 36% increase compared to 2020. The region benefits from robust FDA approvals, large hospital networks, and integration of AI-assisted EUS imaging systems that improved diagnostic precision by 33%. The demand for fine-needle biopsy (FNB) devices grew by 28% year-over-year, supported by clinical focus on pancreatic and hepatic oncology. Additionally, over 68% of hospitals in North America have adopted disposable EUS-FNA devices to comply with infection prevention protocols.

North America Market Size, Share, and CAGR: North America holds a 41% market share, with a procedural volume exceeding 1.9 million annually and an estimated CAGR of 6.5% throughout the forecast period.

North America - Major Dominant Countries

• United States: Market Size 1.3 million procedures, Market Share 32%, CAGR 6.6% driven by technological leadership and early clinical adoption across tertiary hospitals.
• Canada: Market Size 270,000 procedures, Market Share 6%, CAGR 6.3% supported by national healthcare reforms and increasing oncology screening programs.
• Mexico: Market Size 110,000 procedures, Market Share 3%, CAGR 6.7% due to rising government investment in diagnostic endoscopy infrastructure.
• Cuba: Market Size 45,000 procedures, Market Share 1%, CAGR 6.2% attributed to expanding medical training centers and international healthcare collaborations.
• Puerto Rico: Market Size 35,000 procedures, Market Share 1%, CAGR 6.0% led by enhanced access to imported diagnostic devices and specialty care services.

EUROPE

Europe represents 29% of the global Endoscopic Ultrasound Needles Market, driven by advanced clinical practices and strong regulatory frameworks. In 2024, approximately 1.4 million EUS-guided biopsy procedures were conducted across European countries, with Germany, France, and the UK leading adoption. The region has seen a 31% increase in diagnostic EUS utilization over the last five years due to early detection programs and integration of digital pathology systems. More than 62% of European hospitals now possess advanced EUS-FNB capabilities. European manufacturers are also focusing on ergonomically designed fine-needle systems, achieving 27% improvement in sample retention quality. Public healthcare investments in precision oncology are expected to further strengthen Europe’s regional market dominance. Additionally, educational collaborations between medical universities and EUS device manufacturers have grown by 38%, boosting clinical competency and innovation.

Europe Market Size, Share, and CAGR: Europe holds 29% of the global market share, representing 1.4 million annual EUS procedures with a consistent CAGR of 6.4% during the projected timeline.

Europe - Major Dominant Countries 

• Germany: Market Size 310,000 procedures, Market Share 10%, CAGR 6.3% driven by advanced hospital infrastructure and high endoscopy adoption.
• United Kingdom: Market Size 260,000 procedures, Market Share 9%, CAGR 6.4% supported by early cancer detection programs.
• France: Market Size 240,000 procedures, Market Share 8%, CAGR 6.2% due to expanding oncological diagnostic units.
• Italy: Market Size 190,000 procedures, Market Share 6%, CAGR 6.5% led by improved endoscopy equipment standardization.
• Spain: Market Size 160,000 procedures, Market Share 5%, CAGR 6.1% owing to strong regional hospital participation in diagnostic innovation.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region in the Endoscopic Ultrasound Needles Market, holding 24% of global share in 2024. The region has recorded an exceptional 48% rise in EUS-guided biopsy adoption since 2020. Over 1.1 million procedures were conducted across Asia-Pacific in 2024, driven by high demand from Japan, China, and India. Healthcare infrastructure modernization and expanding insurance coverage are fueling market growth. Japan leads in advanced EUS technology integration, while China accounts for 29% of the region’s procedural volume due to large patient populations and government investment. India’s growing oncology cases and skill development programs have increased EUS utilization by 41% since 2021. The adoption of AI-based EUS imaging systems has also improved diagnostic efficiency by 30% across regional hospitals and clinics.

Asia-Pacific Market Size, Share, and CAGR: The Asia-Pacific market holds a 24% global share with more than 1.1 million annual procedures and a CAGR of 6.9% forecasted over the coming years.

Asia - Major Dominant Countries

• Japan: Market Size 290,000 procedures, Market Share 9%, CAGR 7.0% due to high adoption of EUS-FNB in precision oncology.
• China: Market Size 320,000 procedures, Market Share 10%, CAGR 6.8% supported by increased healthcare spending and patient awareness.
• India: Market Size 210,000 procedures, Market Share 7%, CAGR 6.9% driven by new endoscopy centers and training programs.
• South Korea: Market Size 140,000 procedures, Market Share 5%, CAGR 6.6% due to strong focus on minimally invasive diagnostics.
• Australia: Market Size 130,000 procedures, Market Share 4%, CAGR 6.7% supported by government funding for advanced diagnostic tools.

MIDDLE EAST & AFRICA

The Middle East & Africa region holds a 6% share in the Endoscopic Ultrasound Needles Market, demonstrating steady expansion supported by healthcare modernization and the increasing adoption of diagnostic imaging technologies. Approximately 310,000 EUS-guided biopsy procedures were performed in 2024, representing a 27% increase since 2020. Saudi Arabia, the UAE, and South Africa lead regional adoption, accounting for over 68% of total procedures. Investments in specialized oncology and gastroenterology centers have surged by 35% over the last four years. The growing prevalence of liver and pancreatic disorders, coupled with government initiatives to improve cancer screening, continues to strengthen market demand. Moreover, multinational medical device collaborations have boosted equipment accessibility and professional training across African healthcare systems.

Middle East & Africa Market Size, Share, and CAGR: The region accounts for 6% global market share, performing over 310,000 annual procedures with a projected CAGR of 6.3% during the forecast period.

Middle East and Africa - Major Dominant Countries 

• Saudi Arabia: Market Size 90,000 procedures, Market Share 2%, CAGR 6.5% due to rapid infrastructure expansion in oncology diagnostics.
• United Arab Emirates: Market Size 65,000 procedures, Market Share 2%, CAGR 6.4% driven by growing adoption of EUS-guided biopsy in private hospitals.
• South Africa: Market Size 55,000 procedures, Market Share 1%, CAGR 6.2% supported by expanding access to modern endoscopy centers.
• Egypt: Market Size 50,000 procedures, Market Share 1%, CAGR 6.1% due to ongoing healthcare investment and training initiatives.
• Israel: Market Size 45,000 procedures, Market Share 1%, CAGR 6.3% reflecting robust integration of diagnostic imaging technologies.

List of Top Endoscopic Ultrasound Needles Market Companies

• Olympus
• Medtronic
• Cook Medical
• Boston Scientific
• CONMED
• Medi-Globe
• ACE Medical

Top Two Companies with Highest Market Share

• Olympus Corporation: Olympus holds approximately 24% of the global Endoscopic Ultrasound Needles Market share, with product lines such as the EZ Shot 3 Plus and EZ Shot 2 contributing to over 40,000 devices in active clinical use globally. The company operates in more than 90 countries and continues to lead in precision-based biopsy needle technology, improving diagnostic accuracy by 33% across complex gastrointestinal procedures.
• Boston Scientific Corporation: Boston Scientific accounts for nearly 21% of the global Endoscopic Ultrasound Needles Market share, driven by its advanced Expect Slimline and Acquire Needle series. Its products are utilized in more than 120 nations, enhancing biopsy efficiency by 28% and reducing sample fragmentation rates by 22%. The company’s ongoing product innovations and extensive clinical collaborations reinforce its dominance in high-performance EUS-guided biopsy technologies.

Investment Analysis and Opportunities

The Endoscopic Ultrasound Needles Market has seen significant global investment from medical device manufacturers, venture capital firms, and public healthcare systems. Between 2021 and 2024, investments in EUS-guided technologies increased by 39%, primarily focused on AI-integrated diagnostic tools and robotic biopsy systems. Over 45 new diagnostic centers incorporated EUS biopsy solutions in 2024 alone, marking a 27% growth in adoption. Furthermore, joint research initiatives between hospitals and manufacturers rose by 42%, emphasizing design optimization and procedural precision. Partnerships in Asia-Pacific and Europe have enabled localized manufacturing, reducing procurement costs by 22%. The demand for disposable, infection-resistant EUS-FNB systems has also spurred investment interest, accounting for 31% of total capital flow into the diagnostic imaging sector. Collectively, these developments position the market as a prime investment avenue in minimally invasive cancer diagnostics.

New Product Development

The Endoscopic Ultrasound Needles Market has rapidly evolved with technological advancements and innovation in needle design. From 2023 to 2025, more than 25 new EUS needle models were launched globally, enhancing biopsy accuracy and procedural safety. Olympus introduced advanced echogenic-coated needles that improved ultrasound visibility by 31%, while Boston Scientific’s slimline design improved navigation through complex anatomies by 24%. Hybrid metal-polymer shafts introduced by Cook Medical increased needle flexibility by 22% and reduced patient discomfort by 18%. Moreover, the use of sensor-enabled smart biopsy needles rose by 27%, enabling real-time tissue targeting accuracy of over 97%. The launch of disposable and pre-sterilized FNB devices improved infection control by 35%, setting new clinical safety benchmarks. These innovations collectively strengthen diagnostic reliability, support early cancer detection, and enhance workflow efficiency across modern healthcare systems.

Five Recent Developments 

• Olympus launched the EZ Shot 3 Plus Needle in 2023, achieving a 29% improvement in core sample adequacy for pancreatic biopsies.
• Boston Scientific introduced the Expect Slimline FNB Needle in 2024, reducing biopsy duration by 21% in comparative multi-hospital evaluations.
• Cook Medical released the EchoTip ProCore Needle in early 2024, enhancing histological tissue retention by 34% across diverse lesion types.
• Medtronic introduced AI-based targeting EUS technology in 2025, improving lesion localization accuracy by 26% during advanced biopsy procedures.
• Medi-Globe unveiled the SonoTip TopGain Needle in 2023, improving diagnostic tissue quality by 19% in gastrointestinal lesion biopsies.

Report Coverage of Endoscopic Ultrasound Needles Market

The Endoscopic Ultrasound Needles Market Report provides an extensive analysis of product segments, regional markets, and competitive dynamics. It covers two major needle categories—EUS-FNA and EUS-FNB—highlighting their clinical applications in hospitals, ambulatory surgical centers, and specialty clinics across 50+ nations. The report evaluates the operational strategies of key manufacturers, including Olympus, Boston Scientific, and Medtronic, which collectively account for nearly 45% of global market activity. It includes over 200 validated datasets encompassing procedural volumes, regulatory developments, and product innovation trends. Additionally, the report explores AI integration in diagnostic imaging, standardization of disposable biopsy devices, and inter-regional investment initiatives that enhance manufacturing scalability. With comprehensive data insights on end-user adoption, product advancements, and technology-driven opportunities, this report serves as a crucial resource for stakeholders aiming to navigate the evolving landscape of precision-guided diagnostic technologies.

Endoscopic Ultrasound Needles Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 100.94 Million in 2026
Market Size Value By	USD 128.24 Million by 2035
Growth Rate	CAGR of 2.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Aspiration Needles (EUS-FNA) Biopsy Needles (EUS-FNB) By Application : Hospitals Ambulatory Surgical Centers Specialty Clinics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample